Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is that the federal communication freeze across health agencies is expected to ease by February 1, which should provide more clarity on the administration’s direction.

However, concerns have emerged regarding a significant halt in NIH funding, disruptions in scheduled meetings for ongoing and proposed trials for 2025, and the removal of publicly posted regulations related to diversity initiatives. While some argue these policies were not strongly enforced previously, their sudden absence raises uncertainty about future regulatory actions.

On a positive note, research that had been previously approved and grandfathered in is allowed to continue despite the communication freeze. At KLF, we are closely monitoring these developments, analyzing the latest updates, and advising our clients on navigating these evolving challenges. While uncertainty remains, no news is not necessarily bad news, and we are committed to keeping our clients informed and compliant. 

Support the show